{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:13:24Z","timestamp":1793056404280,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08664-3","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:26:56Z","timestamp":1784341616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The CAFs-derived YAP1-periostin axis forms a fibrotic tumor microenvironment to promote metastatic lung tumor growth"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4927-3897","authenticated-orcid":false,"given":"Jieheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoqin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"issue":"10","key":"8664_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/bmc.2953","volume":"27","author":"I Ali","year":"2013","unstructured":"Ali I, Haque A, Wani WA, Saleem K, Al Za\u2019abi M. Analyses of anticancer drugs by capillary electrophoresis: a review. Biomed Chromatogr: BMC. 2013;27(10):1296\u2013311. https:\/\/doi.org\/10.1002\/bmc.2953.","journal-title":"Biomed Chromatogr: BMC"},{"issue":"1","key":"8664_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/157488512800389164","volume":"7","author":"IA Ali","year":"2012","unstructured":"Ali IA, A. Wani W, Saleem K, Haque A. Thalidomide: a banned drug resurged into future anticancer drug. CDTH. 2012;7(1):13\u201323. https:\/\/doi.org\/10.2174\/157488512800389164.","journal-title":"CDTH"},{"key":"8664_CR3","unstructured":"Ali1 IA, R-U-D KS, Hassan Y, Aboul-Enein2 A. Rather1: social aspects of cancer genesis. Cancer Ther. 2011;8:6\u201314."},{"issue":"1","key":"8664_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clinicians. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clinicians"},{"issue":"8","key":"8664_CR5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.4155\/fmc.13.62","volume":"5","author":"I Ali","year":"2013","unstructured":"Ali I, Wani WA, Haque A, Saleem K. Glutamic acid and its derivatives: candidates for rational design of anticancer drugs. Future Med Chem. 2013;5(8):961\u201378. https:\/\/doi.org\/10.4155\/fmc.13.62.","journal-title":"Future Med Chem"},{"issue":"20","key":"8664_CR6","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2174\/0929867323666160405111152","volume":"23","author":"I Ali","year":"2016","unstructured":"Ali I, Nadeem Lone M, Suhail M, Danish Mukhtar S, Asnin L. Advances in nanocarriers for anticancer drugs delivery. CMC. 2016;23(20):2159\u201387. https:\/\/doi.org\/10.2174\/0929867323666160405111152.","journal-title":"CMC"},{"issue":"1","key":"8664_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/157340613804488297","volume":"9","author":"IW Ali","year":"2013","unstructured":"Ali IW, A. Wani W, Saleem K, Wesselinova D. Syntheses, DNA binding and anticancer profiles of L-Glutamic acid ligand and its Copper(II) and Ruthenium(III) complexes. Med Chem. 2013;9(1):11\u201321. https:\/\/doi.org\/10.2174\/157340613804488297.","journal-title":"Med Chem"},{"issue":"13","key":"8664_CR8","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1016\/j.bmc.2013.04.018","volume":"21","author":"I Ali","year":"2013","unstructured":"Ali I, Haque A, Saleem K, Hsieh MF. Curcumin-I Knoevenagel\u2019s condensates and their Schiff\u2019s bases as anticancer agents: synthesis, pharmacological and simulation studies. Bioorg Med Chem. 2013;21(13):3808\u201320. https:\/\/doi.org\/10.1016\/j.bmc.2013.04.018.","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"8664_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2174\/1871520611313020016","volume":"13","author":"I Ali","year":"2013","unstructured":"Ali I, Wani WA, Saleem K, Haque A. Platinum compounds: a hope for future cancer chemotherapy. ACAMC. 2013;13(2):296\u2013306. https:\/\/doi.org\/10.2174\/1871520611313020016.","journal-title":"ACAMC"},{"issue":"10","key":"8664_CR10","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56(10):2188\u2013205. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.011.","journal-title":"Immunity"},{"issue":"4","key":"8664_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41568-023-00549-7","volume":"23","author":"M Tsoumakidou","year":"2023","unstructured":"Tsoumakidou M. The advent of immune stimulating CAFs in cancer. Nat Rev Cancer. 2023;23(4):258\u201369. https:\/\/doi.org\/10.1038\/s41568-023-00549-7.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"8664_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386. https:\/\/doi.org\/10.1038\/s41568-019-0238-1.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"8664_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12943-024-02180-y","volume":"23","author":"X Zhou","year":"2024","unstructured":"Zhou X, Han J, Zuo A, Ba Y, Liu S, Xu H, et al. THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K\/AKT activation in colorectal cancer. Mol Cancer. 2024;23(1):282. https:\/\/doi.org\/10.1186\/s12943-024-02180-y.","journal-title":"Mol Cancer"},{"issue":"20","key":"8664_CR14","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/0008-5472.CAN-22-1695","volume":"82","author":"CL Hong","year":"2022","unstructured":"Hong CL, Yu IS, Pai CH, Chen JS, Hsieh MS, Wu HL, et al. CD248 regulates wnt signaling in pericytes to promote angiogenesis and tumor growth in lung cancer. Cancer Res. 2022;82(20):3734\u201350. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-1695.","journal-title":"Cancer Res"},{"key":"8664_CR15","doi-asserted-by":"publisher","unstructured":"Wu J, Zhang Q, Wu J, Yang Z, Liu X, Lou C, et al. IL-8 from CD248-expressing cancer-associated fibroblasts generates cisplatin resistance in non-small cell lung cancer. J Cellular Mol Medi. 2024;28(4):e18185. https:\/\/doi.org\/10.1111\/jcmm.18185.","DOI":"10.1111\/jcmm.18185"},{"issue":"1","key":"8664_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.7150\/thno.89495","volume":"14","author":"S Lu","year":"2024","unstructured":"Lu S, Gan L, Lu T, Zhang K, Zhang J, Wu X, et al. Endosialin in cancer: expression patterns, mechanistic insights, and therapeutic approaches. Theranostics. 2024;14(1):379\u201391. https:\/\/doi.org\/10.7150\/thno.89495.","journal-title":"Theranostics"},{"issue":"1","key":"8664_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12929-024-01001-0","volume":"31","author":"YK Hong","year":"2024","unstructured":"Hong YK, Lin YC, Cheng TL, Lai CH, Chang YH, Huang YL, et al. TEM1\/endosialin\/CD248 promotes pathologic scarring and TGF-\u03b2 activity through its receptor stability in dermal fibroblasts. J Biomed Sci. 2024;31(1):12. https:\/\/doi.org\/10.1186\/s12929-024-01001-0.","journal-title":"J Biomed Sci"},{"issue":"11","key":"8664_CR18","doi-asserted-by":"publisher","first-page":"167864","DOI":"10.1016\/j.bbadis.2022.166521","volume":"1868","author":"J Wu","year":"2022","unstructured":"Wu J, Liu X, Wu J, Lou C, Zhang Q, Chen H, et al. CXCL12 derived from CD248-expressing cancer-associated fibroblasts mediates M2-polarized macrophages to promote nonsmall cell lung cancer progression. Biochim Et Biophys Acta (BBA) - Mol Basis Disease. 2022;1868(11):167864. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166521.","journal-title":"Biochim Et Biophys Acta (BBA) - Mol Basis Disease"},{"key":"8664_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejca.2017.10.035","volume":"90","author":"Y Guo","year":"2018","unstructured":"Guo Y, Hu J, Wang Y, Peng X, Min J, Wang J, et al. Tumour endothelial marker 1\/endosialin-mediated targeting of human sarcoma. Eur J Cancer. 2018;90:111\u201321. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.035.","journal-title":"Eur J Cancer"},{"key":"8664_CR20","doi-asserted-by":"publisher","first-page":"218102","DOI":"10.1016\/j.canlet.2025.218102","volume":"635","author":"Z Guo","year":"2025","unstructured":"Guo Z, Liu J, Zhang M, Zheng W, Zhuang J, Sun C. Biomechanical networks of the pre-metastatic niche: decoding biophysical determinants of tumor metastatic organotropism. Cancer Lett. 2025;635:218102. https:\/\/doi.org\/10.1016\/j.canlet.2025.218102.","journal-title":"Cancer Lett"},{"issue":"1","key":"8664_CR21","doi-asserted-by":"publisher","first-page":"14343","DOI":"10.1038\/s41598-024-65435-0","volume":"14","author":"J Xiao","year":"2024","unstructured":"Xiao J, Yang Z, Wang S, Liu X, Wang Y, Hu Z, et al. CD248-expressing cancer-associated fibroblasts induce epithelial\u2013mesenchymal transition of non-small cell lung cancer via inducing M2-polarized macrophages. Sci Rep. 2024;14(1):14343. https:\/\/doi.org\/10.1038\/s41598-024-65435-0.","journal-title":"Sci Rep"},{"issue":"1","key":"8664_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12935-022-02714-8","volume":"22","author":"S Dorafshan","year":"2022","unstructured":"Dorafshan S, Razmi M, Safaei S, Gentilin E, Madjd Z, Ghods R. Periostin: biology and function in cancer. Cancer Cell Int. 2022;22(1):315. https:\/\/doi.org\/10.1186\/s12935-022-02714-8.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"8664_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1535-6108(04)00081-9","volume":"5","author":"S Bao","year":"2004","unstructured":"Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt\/PKB pathway. Cancer Cell. 2004;5(4):329\u201339. https:\/\/doi.org\/10.1016\/S1535-6108(04)00081-9.","journal-title":"Cancer Cell"},{"issue":"1","key":"8664_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13075-022-02943-2","volume":"24","author":"F El-Adili","year":"2022","unstructured":"El-Adili F, Lui JK, Najem M, Farina G, Trojanowska M, Sam F, et al. Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications. Arthritis Res Ther. 2022;24(1):251. https:\/\/doi.org\/10.1186\/s13075-022-02943-2.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"8664_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1089\/cbr.2012.1374","volume":"28","author":"G Wu","year":"2013","unstructured":"Wu G, Wang X, Zhang X. Clinical implications of periostin in the liver metastasis of colorectal cancer. Cancer Biother Radiopharm. 2013;28(4):298\u2013302. https:\/\/doi.org\/10.1089\/cbr.2012.1374.","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"8664_CR26","doi-asserted-by":"publisher","first-page":"112090","DOI":"10.1016\/j.celrep.2023.112090","volume":"42","author":"T Wei","year":"2023","unstructured":"Wei T, Wang K, Liu S, Fang Y, Hong Z, Liu Y, et al. Periostin deficiency reduces PD-1+ tumor-associated macrophage infiltration and enhances anti-PD-1 efficacy in colorectal cancer. Cell Rep. 2023;42(2):112090. https:\/\/doi.org\/10.1016\/j.celrep.2023.112090.","journal-title":"Cell Rep"},{"issue":"3","key":"8664_CR27","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.celrep.2019.12.075","volume":"30","author":"H Ma","year":"2020","unstructured":"Ma H, Wang J, Zhao X, Wu T, Huang Z, Chen D, et al. Periostin promotes colorectal tumorigenesis through Integrin-FAK-Src pathway-mediated YAP\/TAZ activation. Cell Rep. 2020;30(3):793\u2013806.e6. https:\/\/doi.org\/10.1016\/j.celrep.2019.12.075.","journal-title":"Cell Rep"},{"issue":"1","key":"8664_CR28","doi-asserted-by":"publisher","first-page":"10422","DOI":"10.1038\/s41467-024-54920-9","volume":"15","author":"CJ Lee","year":"2024","unstructured":"Lee CJ, Jang TY, Jeon SE, Yun HJ, Cho YH, Lim DY, et al. The dysadherin\/MMP9 axis modifies the extracellular matrix to accelerate colorectal cancer progression. Nat Commun. 2024;15(1):10422. https:\/\/doi.org\/10.1038\/s41467-024-54920-9.","journal-title":"Nat Commun"},{"issue":"12","key":"8664_CR29","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1111\/all.16352","volume":"79","author":"NQV Tran","year":"2024","unstructured":"Tran NQV, Kobayashi Y, Nakamura Y, Ishimaru K, Izuhara K, Nakao A. Transcriptomic evidence for T cell-fibroblast-keratinocyte axis via IL -13-periostin-integrin in atopic dermatitis. Allergy. 2024;79(12):3521\u201325. https:\/\/doi.org\/10.1111\/all.16352.","journal-title":"Allergy"},{"issue":"8","key":"8664_CR30","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.7150\/ijbs.108618","volume":"21","author":"Y Wu","year":"2025","unstructured":"Wu Y, Li S, Yu H, Zhang S, Yan L, Guan X, et al. Integrative single-cell and spatial Transcriptomics analysis reveals ECM-remodeling cancer-associated fibroblast-derived POSTN as a key mediator in pancreatic ductal adenocarcinoma progression. Int J Biol Sci. 2025;21(8):3573\u201396. https:\/\/doi.org\/10.7150\/ijbs.108618.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"8664_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10555-024-10233-3","volume":"44","author":"Y De Oliveira Macena","year":"2025","unstructured":"De Oliveira Macena Y, Cezar MEN, Lira CBF, De Oliveira L, Almeida TN, Costa A, et al. The roles of periostin derived from cancer-associated fibroblasts in tumor progression and treatment response. Cancer Metastasis Rev. 2025;44(1):11. https:\/\/doi.org\/10.1007\/s10555-024-10233-3.","journal-title":"Cancer Metastasis Rev"},{"issue":"18","key":"8664_CR32","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1158\/0008-5472.CAN-19-2691","volume":"80","author":"F Yang","year":"2020","unstructured":"Yang F, Wei Y, Han D, Li Y, Shi S, Jiao D, et al. Interaction with CD68 and regulation of GAS6 expression by endosialin in fibroblasts drives recruitment and polarization of macrophages in hepatocellular carcinoma. Cancer Res. 2020;80(18):3892\u2013905. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2691.","journal-title":"Cancer Res"},{"key":"8664_CR33","doi-asserted-by":"publisher","unstructured":"Wu J, Zhang Q, Yang Z, Xu Y, Liu X, Wang X, et al. CD248-expressing cancer-associated fibroblasts induce non-small cell lung cancer metastasis via Hippo pathway-mediated extracellular matrix stiffness. J Cellular Mol Medi. 2024;28(16):e70025. https:\/\/doi.org\/10.1111\/jcmm.70025.","DOI":"10.1111\/jcmm.70025"},{"issue":"7","key":"8664_CR34","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/2159-8290.CD-23-0426","volume":"14","author":"J Ye","year":"2024","unstructured":"Ye J, Baer JM, Faget DV, Morikis VA, Ren Q, Melam A, et al. Senescent CAFs mediate immunosuppression and drive breast cancer progression. Cancer Discov. 2024;14(7):1302\u201323. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0426.","journal-title":"Cancer DiscovCancer Discov"},{"key":"8664_CR35","doi-asserted-by":"publisher","first-page":"1635915","DOI":"10.3389\/fcell.2025.1635915","volume":"13","author":"Z Yang","year":"2025","unstructured":"Yang Z, Wang X, Zhu X, Li L, Zeng X, Ren J, et al. CD248 induces PD-L1 expression on cancer-associated fibroblasts to promote NSCLC immune escape. Front Cell Dev Biol. 2025;13:1635915. https:\/\/doi.org\/10.3389\/fcell.2025.1635915.","journal-title":"Front Cell Dev Biol"},{"issue":"14","key":"8664_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/cancers14143482","volume":"14","author":"FA Akinjiyan","year":"2022","unstructured":"Akinjiyan FA, Dave RM, Alpert E, Longmore GD, Fuh KC. DDR2 expression in Cancer-associated Fibroblasts promotes ovarian Cancer tumor invasion and metastasis through periostin-ITGB1. Cancers (Basel). 2022;14(14):14. https:\/\/doi.org\/10.3390\/cancers14143482.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"8664_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.7150\/ijbs.52319","volume":"17","author":"Y Li","year":"2021","unstructured":"Li Y, Sun C, Tan Y, Zhang H, Li Y, Zou H. ITGB1 enhances the radioresistance of human non-small cell lung cancer cells by modulating the DNA damage response and YAP1-induced epithelial-mesenchymal transition. Int J Biol Sci. 2021;17(2):635\u201350. https:\/\/doi.org\/10.7150\/ijbs.52319.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"8664_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12885-023-10731-7","volume":"23","author":"S Lu","year":"2023","unstructured":"Lu S, Lu T, Zhang J, Gan L, Wu X, Han D, et al. CD248 promotes migration and metastasis of osteosarcoma through ITGB1-mediated FAK-paxillin pathway activation. BMC Cancer. 2023;23(1):290. https:\/\/doi.org\/10.1186\/s12885-023-10731-7.","journal-title":"BMC Cancer"},{"issue":"10","key":"8664_CR39","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1016\/j.ymthe.2022.05.021","volume":"30","author":"J Wu","year":"2022","unstructured":"Wu J, Chen Y, Liao Z, Liu H, Zhang S, Zhong D, et al. Self-amplifying loop of NF-\u03baB and periostin initiated by PIEZO1 accelerates mechano-induced senescence of nucleus pulposus cells and intervertebral disc degeneration. Mol Ther. 2022;30(10):3241\u201356. https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.021.","journal-title":"Mol Ther"},{"key":"8664_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.matbio.2023.05.006","volume":"121","author":"T Wu","year":"2023","unstructured":"Wu T, Xiong S, Chen M, Tam BT, Chen W, Dong K, et al. Matrix stiffening facilitates the collective invasion of breast cancer through the periostin-integrin mechanotransduction pathway. Matrix Biol. 2023;121:22\u201340. https:\/\/doi.org\/10.1016\/j.matbio.2023.05.006.","journal-title":"Matrix Biol"},{"issue":"1","key":"8664_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12890-016-0211-7","volume":"16","author":"D Bartis","year":"2016","unstructured":"Bartis D, Crowley LE, D\u2019Souza VK, Borthwick L, Fisher AJ, Croft AP, et al. Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis. BMC Pulm Med. 2016;16(1):51. https:\/\/doi.org\/10.1186\/s12890-016-0211-7.","journal-title":"BMC Pulm Med"},{"key":"8664_CR42","doi-asserted-by":"publisher","unstructured":"Hsieh TT, Ku YC, Chen CJ, Kuo CH, Chang BI, Yu CH, et al. CD248 deficiency promotes angiotensin II-induced aortic lesion by attenuating receptor stability in smooth muscle cells. Clin Transl Med. 2025;15(5):e70352. https:\/\/doi.org\/10.1002\/ctm2.70352.","DOI":"10.1002\/ctm2.70352"},{"key":"8664_CR43","doi-asserted-by":"publisher","first-page":"148730","DOI":"10.1016\/j.gene.2024.148730","volume":"927","author":"L Zhang","year":"2024","unstructured":"Zhang L, Shang Y, Han C, Li M, Zhang J, Li Y, et al. CD248 interacts with ECM to promote hypertrophic scar formation and development. Gene. 2024;927:148730. https:\/\/doi.org\/10.1016\/j.gene.2024.148730.","journal-title":"Gene"},{"issue":"11","key":"8664_CR44","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337. https:\/\/doi.org\/10.1038\/nm.3394.","journal-title":"Nat Med"},{"issue":"1","key":"8664_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-023-01436-2","volume":"16","author":"S-YM Liu","year":"2023","unstructured":"Liu S-YM, Zheng MM, Pan Y, Liu SY, Li Y, Wu YL. Emerging evidence and treatment paradigm of non-small cell lung cancer. J Hematol Oncol. 2023;16(1):40. https:\/\/doi.org\/10.1186\/s13045-023-01436-2.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"8664_CR46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41571-025-01021-1","volume":"22","author":"Z Rahal","year":"2025","unstructured":"Rahal Z, El Darzi R, Moghaddam SJ, Cascone T, Kadara H. Tumour and microenvironment crosstalk in NSCLC progression and response to therapy. Nat Rev Clin Oncol. 2025;22(7):463\u201382. https:\/\/doi.org\/10.1038\/s41571-025-01021-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"8664_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","volume":"18","author":"H Jia","year":"2025","unstructured":"Jia H, Chen X, Zhang L, Chen M. Cancer associated fibroblasts in cancer development and therapy. J Hematol Oncol. 2025;18(1):36. https:\/\/doi.org\/10.1186\/s13045-025-01688-0.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"8664_CR48","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-025-02379-7","volume":"24","author":"G Chen","year":"2025","unstructured":"Chen G, Chen B, Wu Y, Nie H, Zhong Z, Yang S, et al. Bridging the tumor microenvironment: the pivotal role of cancer-associated fibroblasts in tumor cachexia development. Mol Cancer. 2025;24(1):194. https:\/\/doi.org\/10.1186\/s12943-025-02379-7.","journal-title":"Mol Cancer"},{"issue":"1","key":"8664_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159. https:\/\/doi.org\/10.1186\/s12943-023-01860-5.","journal-title":"Mol Cancer"},{"issue":"5","key":"8664_CR50","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/cac2.12291","volume":"42","author":"D Hu","year":"2022","unstructured":"Hu D, Li Z, Zheng B, Lin X, Pan Y, Gong P, et al. Cancer-associated fibroblasts in breast cancer: challenges and opportunities. Cancer Commun (Lond). 2022;42(5):401\u201334. https:\/\/doi.org\/10.1002\/cac2.12291.","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"8664_CR51","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","volume":"42","author":"L Cords","year":"2024","unstructured":"Cords L, Engler S, Haberecker M, Ruschoff JH, Moch H, de Souza N, et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42(3):396\u2013412.e5. https:\/\/doi.org\/10.1016\/j.ccell.2023.12.021.","journal-title":"Cancer Cell"},{"issue":"22","key":"8664_CR52","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1158\/0008-5472.CAN-24-0932","volume":"84","author":"H Song","year":"2024","unstructured":"Song H, Lu T, Han D, Zhang J, Gan L, Xu C, et al. YAP1 inhibition induces phenotype switching of cancer-associated Fibroblasts to tumor suppressive in prostate Cancer. Cancer Res. 2024;84(22):3728\u201342. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-0932.","journal-title":"Cancer Res"},{"issue":"20","key":"8664_CR53","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1182\/blood.2023023601","volume":"144","author":"S Hu","year":"2024","unstructured":"Hu S, Liu Y, Zhang X, Wang X, Li Y, Chu M, et al. YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia. Blood. 2024;144(20):2136\u201348. https:\/\/doi.org\/10.1182\/blood.2023023601.","journal-title":"Blood"},{"issue":"11","key":"8664_CR54","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/all.13814","volume":"74","author":"K Izuhara","year":"2019","unstructured":"Izuhara K, Nunomura S, Nanri Y, Ono J, Takai M, Kawaguchi A. Periostin: an emerging biomarker for allergic diseases. Allergy. 2019;74(11):2116\u201328. https:\/\/doi.org\/10.1111\/all.13814.","journal-title":"Allergy"},{"issue":"1","key":"8664_CR55","doi-asserted-by":"publisher","first-page":"107472","DOI":"10.1016\/j.celrep.2020.03.036","volume":"31","author":"SK Mishra","year":"2020","unstructured":"Mishra SK, Wheeler JJ, Pitake S, Ding H, Jiang C, Fukuyama T, et al. Periostin activation of Integrin receptors on sensory neurons induces allergic itch. Cell Rep. 2020;31(1):107472. https:\/\/doi.org\/10.1016\/j.celrep.2020.03.036.","journal-title":"Cell Rep"},{"issue":"7","key":"8664_CR56","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.7150\/thno.94207","volume":"14","author":"X Jin","year":"2024","unstructured":"Jin X, Deng Q, Ye S, Liu S, Fu Y, Liu Y, et al. Cancer-associated fibroblast-derived periostin promotes papillary thyroid tumor growth through integrin-FAK-STAT3 signaling. Theranostics. 2024;14(7):3014\u201328. https:\/\/doi.org\/10.7150\/thno.94207.","journal-title":"Theranostics"},{"issue":"1","key":"8664_CR57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12943-026-02649-y","volume":"25","author":"J Li","year":"2026","unstructured":"Li J, Zeng X, Hu E, Zhou H, Huang W. YAP1 in control: how RNA networks and protein modifications shape its function and therapeutic targetability. Mol Cancer. 2026;25(1):25. https:\/\/doi.org\/10.1186\/s12943-026-02649-y.","journal-title":"Mol Cancer"},{"issue":"25","key":"8664_CR58","doi-asserted-by":"publisher","first-page":"8550","DOI":"10.1074\/jbc.RA120.013794","volume":"295","author":"B Cinar","year":"2020","unstructured":"Cinar B, Al-Mathkour MM, Khan SA, Moreno CS. Androgen attenuates the inactivating phospho\u2013Ser-127 modification of yes-associated protein 1 (YAP1) and promotes YAP1 nuclear abundance and activity. J Biol Chem. 2020;295(25):8550\u201359. https:\/\/doi.org\/10.1074\/jbc.RA120.013794.","journal-title":"J Biol Chem"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08664-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08664-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08664-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:08:29Z","timestamp":1791878909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08664-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8664"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08664-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal studies were conducted in accordance with the Animal Use Protocol approved by Guizhou Medical University. The Affiliated Hospital of Guizhou Medical University provided the human NSCLC and matched healthy tissue biopsies for comparison. All participants provided written informed consent before the research began, and the study was authorized by the ethics committee of the same institution. The maximal tumor size\/burden permitted by the Ethics Committee was 1.5\u2009cm in diameter; the maximal tumor size\/burden was not exceeded in the experiments conducted in this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1295"}}